Category Archives: "News"

Genentech’s Ocrelizumab reduced both relapses and disability progression versus Rebif
Genentech’s ocrelizumab Significantly Reduced Both Relapses and Disability Progression versus interferon beta-1a (Rebif®) in Two Phase [...]
Multiple Sclerosis Coalition announces new board President
Multiple Sclerosis Coalition Announces New Board President Lisa Taylor Skutnik elected to lead coalition of MS nonprofits Cherry [...]
Sandoz announces US launch of Glatopa, the first generic competitor to Copaxone 20mg
Sandoz announces US launch of Glatopa™, the first generic competitor to Copaxone® 20mg Glatopa is the first FDA-approved, [...]
Novartis statement on reported case of PML
Novartis Statement on Reported Case of PML Novartis has been informed of a patient with progressive multifocal leukoencephalopathy [...]
FDA accepts biologics license application for ZINBRYTA for treatment of multiple sclerosis
FDA Accepts Biologics License Application For ZINBRYTA (Daclizumab High-Yield Process) For Treatment of MS BLA Acceptance Follows [...]
Mallinckrodt research fellowship award program announcement
Mallinckrodt Research Fellowship Award Program Announcement Mallinckrodt Pharmaceuticals is pleased to announce the Research Fellowship [...]
FDA accepts filing of BETACONNECT for RRMS patients taking BETASERON
FDA Accepts Filing of BETACONNECT™* for Relapsing-Remitting Multiple Sclerosis Patients Taking BETASERON® (interferon beta-1b) Offers [...]
International survey identifies opportunities for improving multiple sclerosis treatment satisfaction
International Survey from Biogen Identifies Opportunities for Improving MS Treatment Satisfaction Many Factors Influence Patient [...]
PLEGRIDY three-year data support long-term safety and efficacy in multiple sclerosis patients
PLEGRIDY® (Peginterferon Beta-1a) Three-Year Data Presented at AAN Annual Meeting Support Long-Term Safety and Efficacy in Multiple [...]
TECFIDERA Data Reinforce Strong, Sustained Efficacy for Newly-Diagnosed MS Patients
TECFIDERA® (Dimethyl Fumarate) Data Reinforce Strong, Sustained Efficacy for Newly-Diagnosed MS Patients TECFIDERA Provides Robust and [...]

CMSC provides leadership in clinical research and education; develops vehicles to share information and knowledge among members; disseminates information to the health care community and to persons affected by MS.

Contact Us
Contact Us
I have a question about
First
Last

Feel Free To contact Us
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Nam molestie, tellus id pellen tesque feugiat, sem sem cursus orci, a placerat ante ante nec massa. consectetuer adipiscing elit.

+1-222-333-4444

New York, NY 10123 USA

Mon - Sat 9:00 AM